D-0119-2017 Class III Terminated

Recalled by Par Pharmaceutical, Inc. — Chestnut Ridge, NY

FDA drug recall D-0119-2017 was initiated by Par Pharmaceutical, Inc. on Sep 27, 2016 and is designated Class III. Reason for recall: Subpotent Drug; Ethinyl Estradiol The recall status is terminated (terminated Nov 5, 2026). Affected quantity: 221,017 tablets.

Recall details

Product Type
Drugs
Report Date
Nov 9, 2016
Initiation Date
Sep 27, 2016
Termination Date
Nov 5, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
221,017 tablets

Product description

Gildess 1.5/30 (norethindrone acetate, 1.5 mg and ethinyl estradiol tablets, 0.03 mg, USP), 21 count, (a) 3 blisters (NDC 0603-7606-48) and (b) 6 blisters (NDC 0603-7606-15), Rx only, Manufactured in Canada By: Patheon, Inc., Ontario, Canada L5N 7K9, Manufactured for QUALITEST PHARMACEUTICALS, USA, Huntsville, AL 35811

Reason for recall

Subpotent Drug; Ethinyl Estradiol

Distribution pattern

Nationwide and Puerto Rico

Code information

Lot Numbers (a) 4169949, 4297235, 4359298, 4501268, 4614353 (b) 4101064, 4196576, 4228443, 4265206, 4265207, 4267685, 4365281, 4365284, 4365289, 4501276, 4563354, 4563355, 4614354, 4731574, 4731575, 4793332, 4798708, 4798709

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0119-2017
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0119-2017. Report a data issue: hello@regdatalab.com.